Vifor Fresenius gains certain rights to Relypsa's Patiromer FOS

11 August 2015

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has entered into an exclusive partnership to commercialize Patiromer for Oral Suspension (Patiromer FOS), US biotech firm Relypsa's (Nasdaq: RLYP) investigational medicine for the treatment of hyperkalemia. Switzerland-based VFMCRP is a joint venture between Galenica and Fresenius Medical Care.

Under the terms of the agreement, Relypsa will get an upfront cash payment of $40 million and will be eligible to receive payments of up to $125 million upon achieving certain regulatory and sales based milestones. In addition, Relypsa will receive tiered double-digit royalties on net sales of Patiromer FOS in the licensed territories.

VFMCRP will obtain an exclusive marketing right from Relypsa in worldwide territories except the USA and Japan, where Relypsa retains all commercial rights. VFMCRP and Relypsa will collaborate on ongoing development of Patiromer FOS, including submission of a Marketing Authorization Application (MAA) with the European Medicines Agency.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK